Ionis Pharmaceuticals' stake in the muscular disease treatment developer will be cut in an offering set to raise between $95m and $107m.

All 17 founding health systems have chipped into the health data platform developer’s series A round, which closed with contributions from three new members.

Electric aircraft developer Heart Aerospace raised $35m from investors including Mesa Air and United, while several corporates are set to exit remote access software developer Openpath.

GV has contributed to two rounds for the gene-editing technology developer, which publicly launched yesterday with $315m of funding.

Access Biotechnology helped the small molecule drug developer increase its total funding to over $300m in a round led by BVF Partners.

Tigermed and WuXi Biologics took part in the biopharmaceutical company's series D round, which will accelerate the development of its immuno-oncology drug candidates.

Existing investor Agilent helped the biomedical analysis technology developer close a series C round that pushed its overall funding past $110m.

Lilly Asia Ventures co-led a series A round for ProfoundBio that will help it develop its novel technology and targeted cancer therapeutics.

IP Group has returned for a series C round for the PNNL spinout, having already backed the series A and B rounds.

Th heart disease treatment developer has secured $248m in funding since being formed to exploit UT Southwestern and Gladstone Institute research.